Drug Trial Radar · NCT06684795
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
May 1, 2024
Primary completion
Jun 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In neurosurgery both the diffusely infiltrated gliomas of the brain as well as the border towards healthy tissue in the meninges is a challenge. For the high-grade contrast enhanced gliomas fluorescent drugs like Gliolan have been used in several years and proved its clinical value. For non-contrast enhanced gliomas, like low-grade glioma, no such drug exist. The transition zone towards healthy non-tumor cell infiltrated brain in such low-grade gliomas is extremely difficult but for these patients their prognosis depends on the amount of non-healthy tissue left behind. Also, in benign tumors as meningioma the complete resection including infiltrated meninges is of importance for the cure of the disease. None of the existing fluorescent drug is useful or approved for these tumors.. Hence a medicinal product that will fulfil the criteria for a safe and reliable fluorescent drug to guide the surgery to the boundaries of the infiltration with tumor cells is highly warranted.
Conditions
- Low-grade Glioma
- Meningioma
- Glioma
Interventions
FG001 prior to surgeryDrug
Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectiveTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Capital Region, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.